Education
About Us
Working with TipRanks
Follow Us
Agenus Inc. (AGEN)
:AGEN
AGEN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $19.69
Previous CloseN/A
Volume199.21K
Average Volume (3M)468.76K
Market Cap
$41.00M
Enterprise Value$472.54M
Total Cash (Recent Filing)$13.94M
Total Debt (Recent Filing)$49.94M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
May 13, 2025EPS Estimate
-1.6Last Dividend Ex-Date
Apr 26, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-10.69
Shares Outstanding25,308,842
10 Day Avg. Volume422,871
30 Day Avg. Volume468,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.39
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap11.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.99
Enterprise Value/Ebitda-4.66
Forecast
1Y Price Target
$7.00Price Target Upside332.10% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Agenus News
PremiumCompany Announcements
Agenus Inc. Earnings Call: Mixed Sentiments and Strategic Focus
PremiumCompany Announcements
Agenus Inc. Reports Strategic Cost Reductions and BOT/BAL Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsBOT/BAL has shown strong data with a potentially differentiated profile in neoadjuvant CRC across both MSS and microsatellite instability-high (MSI-H) tumor types.
Financial PerformanceThe company reported operating expenses of $28.7M, which was a ~50% decline from 3Q24, and a higher decline than estimated.
Investor ConfidenceLonger follow-up response and survival data are likely to reinvigorate investor confidence in the de-risked nature of the upcoming confirmatory Ph. III study.
Bears Say
Cash Flow ConcernsAGEN's equity weakness is largely attributed to the prolonged cash runway overhang, particularly as an accelerated approval path is not accessible in the near term.
Funding ChallengesThe company would either need to initiate late stage trials or seek a partner to advance these indications toward potential FDA approval.
Regulatory ChallengesNext steps for Bot/Bal commercialization path are unclear.
---
Ownership Overview
11.45% Insiders
18.17% Mutual Funds
5.50% Other Institutional Investors
55.54% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGEN FAQ
What was Agenus Inc.’s price range in the past 12 months?
Agenus Inc. lowest stock price was $1.38 and its highest was $19.69 in the past 12 months.
What is Agenus Inc.’s market cap?
Agenus Inc.’s market cap is $41.00M.
When is Agenus Inc.’s upcoming earnings report date?
Agenus Inc.’s upcoming earnings report date is May 13, 2025 which is in 31 days.
How were Agenus Inc.’s earnings last quarter?
Agenus Inc. released its earnings results on Mar 11, 2025. The company reported -$2.04 earnings per share for the quarter, beating the consensus estimate of -$2.542 by $0.502.
Is Agenus Inc. overvalued?
According to Wall Street analysts Agenus Inc.’s price is currently Undervalued.
Does Agenus Inc. pay dividends?
Agenus Inc. pays a Notavailable dividend of $0.6 which represents an annual dividend yield of N/A. See more information on Agenus Inc. dividends here
What is Agenus Inc.’s EPS estimate?
Agenus Inc.’s EPS estimate is -1.6.
How many shares outstanding does Agenus Inc. have?
Agenus Inc. has 25,308,842 shares outstanding.
What happened to Agenus Inc.’s price movement after its last earnings report?
Agenus Inc. reported an EPS of -$2.04 in its last earnings report, beating expectations of -$2.542. Following the earnings report the stock price went down -4.651%.
Which hedge fund is a major shareholder of Agenus Inc.?
Among the largest hedge funds holding Agenus Inc.’s share is Oracle Investment Management Inc. It holds Agenus Inc.’s shares valued at 0.
---
Agenus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.00 (332.10% Upside)
$7.00 (332.10% Upside)
Blogger Sentiment
Bullish
AGEN Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 127.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-80.83%
12-Months-Change
Fundamentals
Return on Equity
260.68%
Trailing 12-Months
Asset Growth
-27.92%
Trailing 12-Months
Company Description
Agenus Inc.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
---
AGEN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Agenus' significant progress in reducing operational costs and promising clinical outcomes from BOT/BAL trials, garnering external validation. However, financial challenges such as a reduced cash balance and net loss, along with the temporary shelving of pipeline products, were noted. Nonetheless, the strategic plans to monetize assets and focus on high-potential programs indicate a forward-looking approach.Read More>---
AGEN Stock 12 Month Forecast
Average Price Target
$7.00
▲(332.10% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioCryst
―
Celldex
―
Sarepta Therapeutics
―
Adaptimmune Therapeutics
―
Best Analysts Covering AGEN
1 Year
1 Year Success Rate
1/32 ratings generated profit
1 Year Average Return
-56.15%
reiterated a buy rating 3 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 3.13% of your transactions generating a profit, with an average return of -56.15% per trade.
---